๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Nivolumab plus Ipilimumab in Advanced Melanoma

โœ Scribed by Wolchok, Jedd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Rizvi, Naiyer A.; Lesokhin, Alexander M.; Segal, Neil H.; Ariyan, Charlotte E.; Gordon, Ruth-Ann; Reed, Kathleen; Burke, Matthew M.; Caldwell, Anne; Kronenberg, Stephanie A.; Agunwamba, Blessing U.; Zhang, Xiaoling; Lowy, Israel; Inzunza, Hector David; Feely, William; Horak, Christine E.; Hong, Quan; Korman, Alan J.; Wigginton, Jon M.; Gupta, Ashok; Sznol, Mario


Book ID
120548999
Publisher
Massachusetts Medical Society
Year
2013
Tongue
English
Weight
646 KB
Volume
369
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Nivolumab plus Ipilimumab in Advanced Me
โœ Wolchok, Jedd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Ri ๐Ÿ“‚ Article ๐Ÿ“… 2013 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 646 KB

## BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyteassociated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of t

Ipilimumab in melanoma
โœ Specenier, Pol ๐Ÿ“‚ Article ๐Ÿ“… 2012 ๐Ÿ› Expert Reviews ๐ŸŒ English โš– 949 KB